A crucial step towards expanded vaccine access has been taken, with the Pharmaceutical Benefits Advisory Committee (PBAC) endorsing Covid and RSV immunisation programs. This move has significant implications for various medical fields, including oncology, cardiology, and the treatment of rare diseases.
The Battle Against Covid-19 and RSV: A New Front Opens
The PBAC's December 2025 meeting focused on vaccines, recommending the addition of updated Covid and respiratory syncytial virus (RSV) vaccines to the National Immunisation Program (NIP). This includes the Comirnaty Omicron XBB.1.5 Covid-19 vaccine, which is now recommended for adults at high risk of severe illness, such as older adults and specific Aboriginal and Torres Strait Islander populations.
This recommendation aligns with the latest advice from the Australian Technical Advisory Group on Immunisation (ATAGI). Furthermore, the committee has paved the way for future Covid vaccines using similar technology, acknowledging the ever-changing nature of SARS-CoV-2 variants.
A Necessary Transition: From NCVP to NIP
The PBAC's report highlights that this is the first recommendation for a Covid-19 vaccine, a critical step towards transitioning Covid vaccines from the NCVP to the NIP. The committee emphasizes the ongoing importance of protection against Covid-19, as it was the leading cause of acute respiratory infection mortality in Australia from 2022 to 2024.
However, the PBAC also stresses that cost-effectiveness is a key consideration. While acknowledging the clinical value of vaccination, the committee reiterates that an acceptable cost-effectiveness ratio will depend on revised pricing through negotiations with the vaccine sponsor.
The Cost-Effectiveness Conundrum
The PBAC has advised that the sponsor's economic assumptions are not appropriate and that a more conservative approach should be taken in the analysis. At the proposed price, the PBAC considers the incremental cost-effectiveness ratio (ICER) to be unacceptably high. Therefore, they recommend a lower price to ensure the vaccine is cost-effective in the proposed circumstances.
But here's where it gets controversial: How do we balance the need for protection against the financial implications?
Beyond Vaccines: Expanding Treatment Options
In other areas, the PBAC has recommended an amendment to the PBS restriction for eplerenone in the treatment of heart failure, citing improved tolerability and alignment with contemporary guidelines. For rheumatology patients, the PBAC has supported an increase in the maximum number of repeats for hydroxychloroquine 200mg tablets, improving continuity of care without a significant increase in PBS expenditure.
For spinal muscular atrophy, the PBAC has recommended clarifications to ensure equitable access to nusinersen for children who have received prior gene therapy. This approach aims to provide the best clinical outcomes for all eligible children.
In oncology, the PBAC has recommended a revised proposal for pembrolizumab, allowing a broad multi-cancer PBS listing for advanced and metastatic disease. The committee supports consistency with other immunotherapy listings and endorses risk-sharing arrangements to manage budget impact while maintaining patient access.
A Ray of Hope for Rare Diseases
The PBAC has also recommended the PBS listing of velmanase alfa for the treatment of alpha-mannosidosis, a rare and devastating condition. With no alternative disease-modifying therapies available, this medicine addresses a significant unmet clinical need.
And this is the part most people miss: Rare diseases often face unique challenges in accessing treatments due to their low prevalence, making recommendations like these vital for patients.
All PBAC recommendations are subject to successful price negotiations and federal approval. For the full meeting outcomes, you can refer to the provided link.
What are your thoughts on these recommendations? Do you think the balance between clinical value and cost-effectiveness is being struck appropriately? We'd love to hear your opinions in the comments!
